S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Mirati Therapeutics (MRTX) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.

Mirati Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 14 Analyst Ratings

Analysts' Consensus Price Target

$60.00
2.21% Upside
High Forecast$82.00
Average Forecast$60.00
Low Forecast$37.00
TypeCurrent Forecast
4/18/23 to 4/17/24
1 Month Ago
3/19/23 to 3/18/24
3 Months Ago
1/18/23 to 1/18/24
1 Year Ago
4/18/22 to 4/18/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
11 Hold rating(s)
11 Hold rating(s)
11 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$60.00$60.00$60.00$80.87
Predicted Upside2.21% Upside20.88% Upside20.88% Upside53.45% Upside
Get Mirati Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

MRTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Mirati Therapeutics Stock vs. The Competition

TypeMirati TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.21
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside2.21% Upside941.94% Upside12.08% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/20/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral$48.00 ➝ $59.00+0.37%
11/7/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
11/7/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$78.00 ➝ $58.00+3.07%
11/7/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$83.00 ➝ $59.00+4.85%
10/9/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$58.00+1.72%
10/9/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Patel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$65.00 ➝ $60.00-0.33%
10/9/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Sector Perform$58.00-3.65%
10/9/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$55.00 ➝ $58.00-3.65%
10/9/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
10/6/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$31.00 ➝ $72.00+15.42%
8/9/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$42.00 ➝ $37.00
8/9/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$56.00 ➝ $62.00+123.02%
7/24/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$104.00 ➝ $60.00+93.61%
7/24/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$54.00 ➝ $46.00+46.92%
7/24/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$75.00 ➝ $71.00+126.76%
5/11/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/11/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:49 PM ET.

MRTX Price Target - Frequently Asked Questions

What is Mirati Therapeutics's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Mirati Therapeutics stock is Hold based on the current 11 hold ratings and 3 buy ratings for MRTX. The average twelve-month price prediction for Mirati Therapeutics is $60.00 with a high price target of $82.00 and a low price target of $37.00. Learn more on MRTX's analyst rating history.

Do Wall Street analysts like Mirati Therapeutics more than its competitors?

Analysts like Mirati Therapeutics less than other Medical companies. The consensus rating for Mirati Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how MRTX compares to other companies.

Does Mirati Therapeutics's stock price have much upside?

According to analysts, Mirati Therapeutics's stock has a predicted upside of 20.88% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:MRTX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners